

<sup>18</sup>  
~~2~~. (Twice Amended) The method according to claim <sup>17</sup>~~1~~, wherein the drug-resistant hypercalcemia is resistant to a therapeutic agent for hypercalcemia other than said at least one substance that inhibits the binding between PTHrP and a receptor thereof.

<sup>19</sup>  
~~3~~. (Twice Amended) The method according to claim <sup>18</sup>~~2~~, wherein the therapeutic agent for hypercalcemia is chosen from at least one of a bone resorption-inhibiting agent, a calcium excretion-promoting agent, an agent for inhibiting intestinal absorption of calcium, and a loop diuretic.

<sup>20</sup>  
~~4~~. (Amended) The method according to claim <sup>18</sup>~~2~~, wherein the therapeutic agent for hypercalcemia is a bone resorption-inhibiting agent.

<sup>21</sup>  
~~5~~. (Twice Amended) The method according to claim <sup>20</sup>~~4~~, wherein the bone resorption-inhibiting agent is at least one of bisphosphonate or calcitonin.

<sup>22</sup>  
~~6~~. (Twice Amended) The method according to any one of claims <sup>17</sup>~~1~~ or <sup>18</sup>~~2~~, wherein said at least one substance is an antagonist of the PTHrP receptor.

<sup>23</sup>  
~~7~~. (Twice Amended) The method according to any one of claims <sup>17</sup>~~1~~ or <sup>18</sup>~~2~~, wherein said at least one substance is an anti-PTHrP antibody.

<sup>24</sup>  
~~8~~. (Twice Amended) The method according to any one of claims <sup>17</sup>~~1~~ or <sup>18</sup>~~2~~, wherein said at least one substance is a fragment of an anti-PTHrP antibody or a modified form of the fragment.

<sup>25</sup>  
~~9~~. (Amended) The method according to claim <sup>23</sup>~~7~~, wherein the antibody is monoclonal.

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com

<sup>26</sup>  
~~10~~. (Twice Amended) The method according to claim <sup>23</sup>~~7~~, wherein the antibody is chosen from at least one of a human antibody, a humanized antibody, and a chimeric antibody.

<sup>27</sup>  
~~11~~. (Amended) The method according to claim <sup>23</sup>~~7~~, wherein the antibody is in a humanized form.

<sup>28</sup>  
~~12~~. (Amended) The method according to claim <sup>27</sup>~~11~~, wherein the humanized antibody is humanized #23-57-137-1 antibody.

<sup>29</sup>  
~~13~~. (Twice Amended) The method according to any one of claims <sup>17</sup>~~7~~ or <sup>18</sup>~~2~~, wherein the drug-resistant hypercalcemia is caused by cancer.

<sup>30</sup>  
~~14~~. (Amended) The method according to claim <sup>21</sup>~~5~~, wherein said at least one substance is chosen from at least one of

- a) an antagonist of the PTHrP receptor;
- b) an anti-PTHrP antibody; and
- c) a fragment of an anti-PTHrP antibody or a modified form of the fragment.

<sup>31</sup>  
~~15~~. (Amended) The method of claim <sup>30</sup>~~14~~, wherein the antibody is chosen from at least one of a human antibody, a humanized antibody, and a chimeric antibody.

<sup>32</sup>  
~~16~~. (Amended) The method according to claim <sup>21</sup>~~5~~, wherein the drug-resistant hypercalcemia is caused by cancer.

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com